← Back to Search

Monoclonal Antibodies

XmAb®22841 for Solid Tumors (DUET-4 Trial)

Phase 1
Waitlist Available
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 56 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called XmAb22841 alone and with another drug, pembrolizumab, in patients with advanced solid tumors. The goal is to find the safest dose and see how well these drugs work together. Both drugs aim to boost the immune system to better fight cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option in various cancers, including melanoma, prostate cancer, and endometrial cancer.

Eligible Conditions
  • Advanced or Metastatic Solid Tumors
  • Anal Cancer
  • Liver Cancer
  • Squamous Cell Carcinoma
  • Cervical Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Melanoma
  • Kidney Cancer
  • Colorectal Cancer
  • Nasopharyngeal Carcinoma
  • Small Cell Lung Cancer
  • Nasopharyngeal Cancer
  • Vulvar Squamous Cell Carcinoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Peritoneal Carcinoma
  • Gastric Cancer
  • Penile Cancer
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~56 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 56 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2Experimental Treatment2 Interventions
Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
Group II: Arm 1Experimental Treatment1 Intervention
Arm 1: XmAb®22841 Monotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XmAb®22841
2019
Completed Phase 1
~80
Pembrolizumab (Keytruda®)
2019
Completed Phase 1
~140

Find a Location

Who is running the clinical trial?

Xencor, Inc.Lead Sponsor
30 Previous Clinical Trials
2,574 Total Patients Enrolled
ICON Clinical ResearchIndustry Sponsor
51 Previous Clinical Trials
15,409 Total Patients Enrolled
Benjamin Thompson, MD, PhDStudy DirectorXencor, Inc.
1 Previous Clinical Trials
4 Total Patients Enrolled
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top